Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.
Abstract
Driver-directed therapeutics have revolutionized cancer treatment, presenting similar or better efficacy compared to traditional chemotherapy and substantially improving quality of life. Despite significant advances, targeted therapy is greatly limited by resistance acquisition, which emerges in nearly all patients receiving treatment. As a result, identifying the molecular modulators of resistance is of great interest. Recent work has implicated protein kinase C (PKC) isozymes as mediators of drug resistance in non-small cell lung cancer (NSCLC). Importantly, previous findings on PKC have implicated this family of enzymes in both tumor-promotive and tumor-suppressive biology in various tissues. Here, we review the biological role of PKC isozymes in NSCLC through extensive analysis of cell-line-based studies to better understand the rationale for PKC inhibition. PKC isoforms α, ε, η, ι, ζ upregulation has been reported in lung cancer, and overexpression correlates with worse prognosis in NSCLC patients. Most importantly, PKC isozymes have been established as mediators of resistance to tyrosine kinase inhibitors in NSCLC. Unfortunately, however, PKC-directed therapeutics have yielded unsatisfactory results, likely due to a lack of specific evaluation for PKC. To achieve satisfactory results in clinical trials, predictive biomarkers of PKC activity must be established and screened for prior to patient enrollment. Furthermore, tandem inhibition of PKC and molecular drivers may be a potential therapeutic strategy to prevent the emergence of resistance in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of PKC can upregulate several molecular pathways, including Akt, signal transducer and activator of transcription 3 (STAT3), nuclear factor‐κB (NF‐κB) and apoptotic pathways, to regulate tumorigenesis and metastasis [112].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [112]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The binding of ligands to their receptors can activate phospholipase C, leading to the upregulation of cytosolic concentrations of the activators of PKC signaling, diacylglycerol (DAG) and Ca++ [112, 113].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Lung cancer is the most prevalent cancer and the leading cause of cancer-related mortality worldwide, with an estimated 2,093,900 new cases and 1,761,000 deaths annually [1,2].”
BackgroundSiegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725 · cited 2×
“The discovery of PKC activation by tumor-promoting agent phorbol 12-myristate 13-acetate (PMA) in 1982 [28] drew attention to this family of kinases based on the plethora of cell biologic responses to PMA and other phorbol esters, warranting extensive research that implicated PKC isozymes in various pathologies, inclu…”
BackgroundZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908 · cited 1×
“The current clinical outcomes for lung cancer patients are far from satisfactory, and novel treatments must be developed that improve overall survival (OS) [3].”
BackgroundLung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484 · cited 1×
“NSCLC accounts for the largest subset of lung cancer cases, roughly 85%, and is further categorized into adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma [4,5].”
BackgroundCoussens, L., Parker, P. J., Rhee, L., Yang-Feng, T. L., Chen, E., Waterfield, M. D., Francke, U., & Ullrich, A. (1986) · Science · doi:10.1126/science.3755548 · Cited by 1,042
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
Geraldes, P., & King, G. L. (2010) · Circulation Research · doi:10.1161/circresaha.110.217117 · Cited by 985
Structural Basis of Protein Kinase C Isoform Function
Steinberg, S. F. (2008) · Physiological Reviews · doi:10.1152/physrev.00034.2007 · Cited by 872 · cited 1×
“Biochemical analysis of PKCs revealed a highly conserved C-terminal catalytic domain, with a variable N-terminal regulatory domain (Figure 2) [26].”
BackgroundInoue, M., Kishimoto, A., Takai, Y., & Nishizuka, Y. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41010-6 · Cited by 862 · cited 1×
“Briefly, PKCs were initially discovered in 1977 by the group of Yasutomi Nishizuka [18].”
BackgroundThe Complete Primary Structure of Protein Kinase C—the Major Phorbol Ester Receptor
Parker, P. J., Coussens, L., Totty, N., Rhee, L., Young, S., Chen, E., Stabel, S., Waterfield, M. D., & Ullrich, A. (1986) · Science · doi:10.1126/science.3755547 · Cited by 854
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793 · cited 1×
“Therefore, understanding the mechanisms that drive the emergence of resistance is of interest, and therapeutic approaches that overcome resistance are essential [8].”
BackgroundTakai, Y., Kishimoto, A., Kikkawa, U., Mori, T., & Nishizuka, Y. (1979) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(79)91197-5 · Cited by 731 · cited 1×
“Identification of PKC as a direct effector of diacylglycerol (DAG) defined the primary second messenger function of DAG and connected PKC to the phosphatidylinositol (PI) cycle of signaling [27].”
BackgroundProtein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
The role of protein kinase C activation and the vascular complications of diabetes
DASEVCIMEN, N., & KING, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.016 · Cited by 494
Tissue-specific expression of three distinct types of rabbit protein kinase C
Ohno, S., Kawasaki, H., Imajoh, S., Suzuki, K., Inagaki, M., Yokokura, H., Sakoh, T., & Hidaka, H. (1987) · Nature · doi:10.1038/325161a0 · Cited by 456
Graff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A., Goode, R., Lewis, J. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0071 · Cited by 442
Tissue and cellular distribution of the extended family of protein kinase C isoenzymes
Wetsel, W., Khan, W., Merchenthaler, I., Rivera, H., Halpern, A., Phung, H., Negro-Vilar, A., & Hannun, Y. (1992) · The Journal of cell biology · doi:10.1083/jcb.117.1.121 · Cited by 440 · cited 1×
“PKCγ expression is mainly limited to neuronal tissues [79].”
BackgroundSelf-citationDown-regulation of protein kinase C is due to an increased rate of degradation
Young, S., Parker, P. J., Ullrich, A., & Stabel, S. (1987) · Biochemical Journal · doi:10.1042/bj2440775 · Cited by 430
Osada, S., Mizuno, K., Saido, T. C., Akita, Y., Suzuki, K., Kuroki, T., & Ohno, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45723-7 · Cited by 428
Classification and Pathology of Lung Cancer
Zheng, M. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.003 · Cited by 398 · cited 1×
“NSCLC accounts for the largest subset of lung cancer cases, roughly 85%, and is further categorized into adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma [4,5].”
BackgroundProtein kinase C: perfectly balanced
Newton, A. C. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1442408 · Cited by 335
Activation of Protein Kinase C Triggers Its Ubiquitination and Degradation
Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M., & Foster, D. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.839 · Cited by 334
Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor
Antal, C. E., Hudson, A. M., Kang, E., Zanca, C., Wirth, C., Stephenson, N. L., Trotter, E. W., Gallegos, L. L., Miller, C. J., Furnari, F. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.001 · Cited by 330
Baier, G., Telford, D., Giampa, L., Coggeshall, K. M., Baier-Bitterlich, G., Isakov, N., & Altman, A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53494-3 · Cited by 303 · cited 1×
“Furthermore, novel PKC isoform θ is primarily expressed in hematopoietic cells [80,81].”
BackgroundProtein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270 · cited 2×
“Contradictory results on the biological role of PKCs have led to the conclusion that PKC-mediated biol gy is highly tissue- and isozyme-specific [31].”
BackgroundAtypical Protein Kinase Cι Is an Oncogene in Human Non–Small Cell Lung Cancer
Regala, R. P., Weems, C., Jamieson, L., Khoor, A., Edell, E. S., Lohse, C. M., & Fields, A. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2372 · Cited by 263 · cited 2×
“Elevated expression of PKCι mRNA and protein levels in NSCLC have been attributed to PRKCI gene amplification [57].”
BackgroundProtein kinase C (PKC) family in cancer progression
Koivunen, J., Aaltonen, V., & Peltonen, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.03.033 · Cited by 261 · cited 2×
“In the context of cancer, PKCs are known to regulate several cellular processes, including proliferation, cell cycle progression, angiogenesis, metastasis, apoptosis, and drug resistance (Figure 3) [16].”
BackgroundKris, M. G., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Aronson, S. L., Engelman, J. A., Shyr, Y., Khuri, F. R., Rudin, C. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.cra7506 · Cited by 213
Murray, N. R., Baumgardner, G. P., Burns, D. J., & Fields, A. P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82331-6 · Cited by 202
Atypical Protein Kinase Cι Plays a Critical Role in Human Lung Cancer Cell Growth and Tumorigenicity
Regala, R. P., Weems, C., Jamieson, L., Copland, J. A., Thompson, E. A., & Fields, A. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505402200 · Cited by 181 · cited 3×
“Stable expression of kinase-deficient PKCι impaired anchorage-independent growth of A549, H1299, and ChaGo cells [57,61].”
BackgroundCarducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3447 · Cited by 176
Dean, N. S., McKay, R. A., Miraglia, L. J., Howard, R., Cooper, S. R., Giddings, J., Nicklin, P. L., Meister, L., Ziel, R., Geiger, T. M., et al. (1996) · PubMed · Cited by 175
Identification of three additional members of rat protein kinase C family: gd‐, ϵ‐ and ξ‐subspecies
Ono, Y., Fuji, T., Ogita, K., Kikkawa, U., Igarashi, K., & Nishizuka, Y. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80564-1 · Cited by 173
Purification and characterization of three types of protein kinase C from rabbit brain cytosol.
Jaken, S., & Kiley, S. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.13.4418 · Cited by 165
Clark, A. S., West, K. A., Blumberg, P. M., & Dennis, P. A. (2003) · PubMed · Cited by 161
Lutzny, G., Kocher, T., Schmidt-Supprian, M., Rudelius, M., Klein-Hitpass, L., Finch, A. J., Dürig, J., Wagner, M., Haferlach, C., Kohlmann, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.003 · Cited by 156
Paz-Ares, L., Douillard, J.-Y., Koralewski, P., Manegold, C., Smit, E. F., Reyes, J. M., Chang, G.-C., John, W. J., Peterson, P. M., Obasaju, C. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3299 · Cited by 154
Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Aronson, S. L., Engelman, J. A., Shyr, Y., Khuri, F. R., Rudin, C. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra7506 · Cited by 141 · cited 2×
“Other, less common mutations have been reported and include BRAF, PIK3CA, MET, HER2, MEK1, and NRAS (Figure 1) [6].”
BackgroundHornung, R. L., Pearson, J. W., Beckwith, M., & Longo, D. L. (1992) · PubMed · Cited by 134
Protein kinase Cι: Human oncogene, prognostic marker and therapeutic target
Fields, A. P., & Regala, R. P. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.015 · Cited by 132
Protein kinase C and cardiac dysfunction: a review
Singh, R. M., Cummings, E., Pantos, C. I., & Singh, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9634-3 · Cited by 131
Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma
Ali, S. A., Justilien, V., Jamieson, L., Murray, N. R., & Fields, A. P. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.012 · Cited by 116 · cited 1×
“In a recent study, PKCιwas shown to phosphorylate ELF3 transcription factor, driving the expression of NOTCH3, which, in turn, induced stemness and promoted lung tumor formation in KRAS-mutant NSCLC [67].”
BackgroundProtein Kinase C (PKC) Isozymes and Cancer
Kang, J. (2014) · New Journal of Science · doi:10.1155/2014/231418 · Cited by 106 · cited 2×
“Interestingly, elevated pro in kinase C (PKC) isoforms α, ε, η, and ι have been observed in NSCLC and associated with poor prognosis, hi ting at a potential role in m diating tumorigenesis [9].”
BackgroundProtein kinase C as a tumor suppressor
Newton, A. C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.017 · Cited by 105
Alfonso, S. I., Callender, J. A., Hooli, B., Antal, C. E., Mullin, K., Sherman, M. A., Lesné, S. E., Leitges, M., Newton, A. C., Tanzi, R. E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf6209 · Cited by 103
Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor
Newton, A. C., & Brognard, J. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.002 · Cited by 100
Primary structures of human protein kinase C βI and βII differ only in their C‐terminal sequences
Kubo, K., Ohno, S., & Suzuki, K. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80524-0 · Cited by 96
miR-203 Inhibits Cell Proliferation and Migration of Lung Cancer Cells by Targeting PKCα
Wang, C., Wang, X., Liang, H., Wang, T., Yan, X., Cao, M., Wang, N., Zhang, S., Zen, K., Zhang, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073985 · Cited by 95
Villalona-Calero, M. A., Ritch, P. S., Figueroa, J. A., Otterson, G. A., Belt, R. J., Dow, E., George, S., Leonardo, J. M., McCachren, S., Miller, G. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0779 · Cited by 88
Marrocco, V., Bogomolovas, J., Ehler, E., dos Remedios, C. G., Yu, J., Gao, C., & Lange, S. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.01.029 · Cited by 86
Bae, K., Wang, H., Jiang, G., Chen, M. G., Lü, L., & Xiao, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4037 · Cited by 85 · cited 3×
“Bioinformatic analysis using gene expression databases and immunohistochemistry (IHC) analysis of patient tissues have revealed the upregulation of several PKC isoforms in NSCLC compared to normal lung epithelium.”
BackgroundInfluentialRole of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature
Saxena, A., Scaini, G., Bavaresco, D. V., Leite, C., Valvassoria, S. S., Carvalho, A. F., & Quevedo, J. (2017) · Complex Psychiatry · doi:10.1159/000480349 · Cited by 85
Oncogenic Activity of Ect2 Is Regulated through Protein Kinase Cι-mediated Phosphorylation
Justilien, V., Jameison, L., Der, C. J., Rossman, K. L., & Fields, A. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.196113 · Cited by 79 · cited 1×
“Importantly, the PKCι-regulated phosphorylation of Ect2 was a critical event for the promotion of anchorage-independent growth of H1703 cells [65].”
BackgroundLee, P., Fang, Y., Yamaguchi, H., Wang, W., Chen, T.-C., Hong, X., Ke, B., Xia, W., Wei, Y., Zha, Z., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.007 · Cited by 73
Oh, Y., Herbst, R. S., Burris, H., Cleverly, A., Musib, L., Lahn, M., & Bepler, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3685 · Cited by 69
do Carmo, A., Balça-Silva, J., Matias, D., & Lopes, M. C. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23615 · Cited by 68
Tanwell, C. S., Gescher, A., Bradshaw, T. D., & Pettit, G. R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560420 · Cited by 62
Dale, I. L., & Gescher, A. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430129 · Cited by 59
Kim, E. H., Lee, H., Lee, D.-H., Bae, S., Soh, J., Jeoung, D., Kim, J., Cho, C.-K., Lee, Y.-J., & Lee, Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4344 · Cited by 59 · cited 1×
“In H1299, HSP27 and PKCδ heptapeptide interaction has been linked to drug and radiation resistance [47].”
BackgroundGeiger, T. M., Müller, M., Dean, N. M., & Fabbro, D. (1998) · PubMed · Cited by 58
Caino, M. C., López‐Haber, C., Kissil, J. L., & Kazanietz, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031714 · Cited by 57 · cited 1×
“PKCε downregulation impaired the metastatic potential of intravenously inoculated A549 cells [51].”
BackgroundPKC-Theta in Regulatory and Effector T-cell Functions
Brezar, V., Tu, W. J., & Seddiki, N. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00530 · Cited by 57 · cited 1×
“Furthermore, novel PKC isoform θ is primarily expressed in hematopoietic cells [80,81].”
BackgroundLiu, Y., Wang, B., Wang, J., Wan, W., Sun, R., Zhao, Y., & Zhang, N. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.010 · Cited by 56 · cited 1×
“The specific inhibition of PKCζ was previously shown to regulate NSCLC chemotaxis [71].”
BackgroundYin, N., Liu, Y., Khoór, A., Wang, X., Thompson, E. A., Leitges, M., Justilien, V., Weems, C. R., Murray, N. R., & Fields, A. P. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.002 · Cited by 56 · cited 1×
“Importantly however, lung adenocarcinoma may develop through both PKCι-dependent and PKCι-independent pathways [70].”
BackgroundWang, X., Repasky, E. A., & Liu, H.-T. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4529 · Cited by 54 · cited 1×
“Antisense oligonucleotide-mediated suppression of PKCα demonstrated antitumor activity in LTEPa-2 and A549 by reducing proliferation and invasive phenotype in tissue culture [36,37].”
BackgroundLynch, T. J., Raju, R., Lind, M., Riviere, A., Gatzemeier, U., Dorr, A., Holmlund, J., Yuen, A. R., & Sikic, B. I. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)91766-1 · Cited by 54
Centrosomal PKCβII and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis
Kim, J., Choi, Y.-L., Vallentin, A., Hunrichs, B. S., Hellerstein, M. K., Peehl, D. M., & Mochly-Rosen, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6195 · Cited by 54
Tahara, E., Kadara, H. N., Lacroix, L., Lotan, D., & Lotan, R. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.9.8186 · Cited by 52
Teicher, B. A., Menon, K., Álvarez, E., Shih, C., & Faul, M. M. (2002) · Investigational New Drugs · doi:10.1023/a:1016297611825 · Cited by 50
Targeting PKCε by miR‐143 regulates cell apoptosis in lung cancer
Zhang, N., Su, Y., & Xu, L. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.09.018 · Cited by 50 · cited 1×
“miR-143 has been reported to be downregulated in lung cancer, and its suppression enhanced the proliferation and allowed the evasion of apoptosis in A549 and Calu-1 cells [52].”
BackgroundProtein Kinase C δ Is a Downstream Effector of Oncogenic K-ras in Lung Tumors
Symonds, J. M., Ohm, A. M., Carter, C. J., Heasley, L. E., Boyle, T. A., Franklin, W. A., & Reyland, M. E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1511 · Cited by 50 · cited 1×
“In NSCLC cells with mutant KRAS, targeting PKCδ has been shown to inhibit invasion, migration, and colony formation [46].”
BackgroundDale, I. L., Bradshaw, T. D., Gescher, A. J., & Pettit, G. R. (1989) · PubMed · Cited by 48
Meta-analysis of Oncogenic Protein Kinase Cι Signaling in Lung Adenocarcinoma
Erdogan, E., Klee, E. W., Thompson, E. A., & Fields, A. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2459 · Cited by 47 · cited 1×
“In agreement with this finding, a study identifying targets of PKCι revealed that the downregulation of four downstream effector genes, COPB2, ELF3, RFC4, and PLS1, suppressed the transformed phenotype of A549 [64].”
ResultProtein kinase Cε as a cancer marker and target for anticancer therapy
Totoń, E., Ignatowicz, E., Skrzeczkowska, K., & Rybczyńska, M. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70395-4 · Cited by 46
Büschenfelde, C. M. Z., Wagner, M. M., Lutzny‐Geier, G., Oelsner, M., Feuerstacke, Y., Decker, T. W., Bogner, C., Peschel, C., & Ringshausen, I. (2009) · Leukemia · doi:10.1038/leu.2009.216 · Cited by 46
Tekle, C., Giovannetti, E., Sigmond, J., Graff, J. R., Smid, K., & Peters, G. J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604566 · Cited by 45
Protein Kinase Cα Mediates Erlotinib Resistance in Lung Cancer Cells
Abera, M. B., & Kazanietz, M. G. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.097725 · Cited by 44
Caino, M. C., López‐Haber, C., Kim, J., Mochly‐Rosen, D., & Kazanietz, M. G. (2011) · Oncogene · doi:10.1038/onc.2011.428 · Cited by 43 · cited 1×
“Separately, pharmacological inhibition of PKCε using isoform-specific peptide inhibitor εV1-2 was reported to reduce H358 tumor growth in athymic nude mice [50].”
MethodExpression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer
Lahn, M., Chen, S., Li, S., Chedid, M., Hanna, K. R., Graff, J. R., Sandusky, G. E., Ma, D., Niyikiza, C., Sundell, K. L., et al. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.032 · Cited by 42 · cited 1×
“Expression is higher in adenocarcinoma than squamous cell carcinoma [32].”
BackgroundA phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
Winegarden, J. A. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00447-6 · Cited by 42
Zhang, L. L., Cao, F. F., Wang, Y., Meng, F. L., Zhang, Y., Zhong, D., & Zhou, Q. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1241-3 · Cited by 41
Chiappori, A., Bepler, G., Barlési, F., Soria, J., Reck, M., Bearz, A., Barata, F. J., Scagliotti, G. V., Park, K., Wagle, A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181cee24f · Cited by 40
Determinants of differential doxorubicin sensitivity between SCLC and NSCLC
Singhal, S. S., Wickramarachchi, D., Singhal, J., Yadav, S., Awasthi, Y. C., & Awasthi, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.038 · Cited by 40 · cited 1×
“PKCα has also been implicated in drug sensitivity and resistance acquisition and was reported to mediate doxorubicin sensitivity by phosphorylation of RLIP76 in NSCLC [40,41].”
BackgroundIto, M., Codony, C., Codony‐Servat, J., Lligé, D., CHAIB-OUKADOUR, I., Sun, X., Jing, M., Sun, R., Cai, X., Verlicchi, A., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0446-z · Cited by 37 · cited 1×
“Inhibition of the PKCι-PAK1 pathway significantly reduced cell viability and colony formation of HCC827, H23, and H520 cells, showing efficacy not only in mutant KRAS cells, but also mutant EGFR (∆EGFR) cell lines [69].”
BackgroundDeeds, L., Teodorescu, S., Chu, M., Yu, Q., & Chen, C.-Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306854200 · Cited by 36 · cited 1×
“Antisense downregulation of PKCα and θ in H23 cells resulted in an increased expression of p21, leading to G1 arrest in a p53-independent manner [39].”
BackgroundRitch, P. S., Rudin, C. M., Bitran, J. D., Edelman, M. J., Makalinao, A., Irwin, D. H., Lilenbaum, R., Peterson, P. M., & John, W. J. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.12.012 · Cited by 36
Socinski, M. A., Raju, R. N., Stinchcombe, T. E., Kocs, D. M., Couch, L. S., Barrera, D., Rousey, S. R., Choksi, J. K., Jotte, R. M., Patt, D. A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd42eb · Cited by 36
Sonnemann, J., Gekeler, V., Ahlbrecht, K., Brischwein, K., Liu, C., Bader, P., Müller, C., NIETHAMMER, D., & Beck, J. F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.02.001 · Cited by 36 · cited 2×
“However, PKC and drug sensitivity findings are not limited to PKCα, but are also reported for other isoforms [44].”
BackgroundHanauske, A.-R., Oberschmidt, O., Hanauske-Abel, H. M., Lahn, M. M. F., & Eismann, U. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9038-7 · Cited by 34
Lung Cancer Cells Often Express High Levels of Protein Kinase C Activity
Hirai, M., Gamou, S., Kobayashi, M., & Shimizu, N. (1989) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1989.tb02292.x · Cited by 34 · cited 1×
“Elevated PKCα activity has been observed in A549, PC-9, PC-14, and RERF-LC-MS NSCLC cell lines [34].”
BackgroundProtein kinase C (PKC) as a drug target in chronic lymphocytic leukemia
Kazi, J. U., Kabir, N. N., & Rönnstrand, L. (2013) · Medical Oncology · doi:10.1007/s12032-013-0757-7 · Cited by 32
Salama, M., Liu, M., Clarke, C. J., Espaillat, M. P., Haley, J. D., Jin, T., Wang, D., Obeid, L. M., & Hannun, Y. A. (2019) · Oncogene · doi:10.1038/s41388-019-0950-z · Cited by 31
Self-citationHDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma
Jiang, H., Fu, Q., Song, X., Ge, C., Li, R., Li, Z., Zeng, B., Li, C., Wang, Y., Xue, Y., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10812 · Cited by 29 · cited 1×
“Notably, a recent study reported significantly worse OS in lung adenocarcinoma patients expressing relatively high PKCα protein levels [35].”
BackgroundThe Proto-oncogene PKCι Regulates the Alternative Splicing of Bcl-x Pre-mRNA
Shultz, J. C., Vu, N., Shultz, M. D., Mba-Uzoma, U., Shapiro, B. A., & Chalfant, C. E. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0363 · Cited by 28 · cited 1×
“Additionally, PKCι regulates Bcl-x splicing, promoting survival through anti-apoptotic Bcl-x(L) expression [66].”
BackgroundGescher, A., & Reed, D. J. (1985) · PubMed · Cited by 28
The Enigmatic Protein Kinase C-eta
Basu, A. (2019) · Cancers · doi:10.3390/cancers11020214 · Cited by 26
Chapter 7 Phorbol Ester–Induced Apoptosis and Senescence in Cancer Cell Models
Xiao, L., Caino, M. C., von Burstin, V. A., Oliva, J. L., & Kazanietz, M. G. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)01607-8 · Cited by 25
Mitogenic and drug-resistance mediating effects of PKCα require RLIP76
Singhal, S. S., Yadav, S., Singhal, J., Awasthi, S., & Awasthi, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.07.118 · Cited by 24 · cited 1×
“PKCα has also been implicated in drug sensitivity and resistance acquisition and was reported to mediate doxorubicin sensitivity by phosphorylation of RLIP76 in NSCLC [40,41].”
BackgroundProtein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression
Liu, L., Lei, B., Wang, L., Chang, C., Yang, H., Liu, J., Huang, G., & Xie, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s207211 · Cited by 21 · cited 1×
“Patients with a higher expression of PKCι and glucose transporter GLUT1 showed a poorer prognosis [63].”
BackgroundBradshaw, T. D., Gescher, A. J., & Pettit, G. R. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510125 · Cited by 19
PKCη is a novel prognostic marker in non-small cell lung cancer.
Krasnitsky, E., Baumfeld, Y., Freedman, J., Sion‐Vardy, N., Ariad, S., Novack, V., & Livneh, E. (2012) · PubMed · Cited by 19
He, M., Yang, Z., Zhang, L., Song, C., Li, Y., & Zhang, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175466 · Cited by 19
Vansteenkiste, J., Ramlau, R., von Pawel, J., Antonio, B. S., Eschbach, C., Szczęsna, A., Kennedy, L., Visseren‐Grul, C., Chouaki, N., & Reck, M. (2012) · Oncology · doi:10.1159/000335268 · Cited by 18
Mukohara, T., Nagai, S., Koshiji, M., Yoshizawa, K., & Minami, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01677.x · Cited by 17
Kim, K., Chung, C., Kim, J., Lee, D., Cho, S. Y., Lee, T. H., Cho, H. J., & Yeo, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5992-7 · Cited by 15 · cited 1×
“PKCι and PKCζ are both reported to be downstream effectors of YAP, which regulates the phosphorylation of both atypical PKCs, promoting lung adenocarcinoma tumorigenesis [60].”
BackgroundImamura, N., Horikoshi, Y., Matsuzaki, T., Toriumi, K., Kitatani, K., Ogura, G., Masuda, R., Nakamura, N., Takekoshi, S., & Iwazaki, M. (2013) · PubMed · Cited by 14
Kinase activity of protein kinase cα in serum as a diagnostic biomarker of human lung cancer.
Kang, J., Mori, T., Kitazaki, H., Niidome, T., Takayama, K., Nakanishi, Y., & Katayama, Y. (2013) · PubMed · Cited by 12
PKCη is an anti-apoptotic kinase that predicts poor prognosis in breast and lung cancer
Zurgil, U., Ben-Ari, A., Rotem‐Dai, N., Karp, G., Krasnitsky, E., Frost, S. A., & Livneh, E. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140182 · Cited by 12 · cited 1×
“Although little is known about the biological role of PKCη in NSCLC, PKCη protein levels correlated positively with disease stage, and its overexpression has been linked to poor prognosis in lung cancer [53].”
BackgroundBommareddy, R. R., Patel, R. S., Smalley, T. B., & Acevedo-Duncan, M. E. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s224866 · Cited by 12 · cited 2×
“Western blot analysis of NSCLC cell lines A549, H520, H1299, H292, ChaGo, and Sk-Mes1 showed high PKCι protein levels [59,61].”
BackgroundMethodA Phase I Study of Enzastaurin Combined with Pemetrexed in Advanced Non-small Cell Lung Cancer
Tanai, C., Yamamoto, N., Ohe, Y., Takahashi, T., Kunitoh, H., Murakami, H., Yamamoto, N., Nakamura, Y. K., Nokihara, H., Shukuya, T., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181da3899 · Cited by 8
Wang, X., & Liu, H. T. (1998) · PubMed · Cited by 8
王向阳, & 柳惠图 (1998) · PubMed · Cited by 8
Luo, Q., Tang, L., Lin, H., Huang, J., Zhang, T., Liu, Y., Wang, J., Zhan, P., Yin, X., Su, X., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.029 · Cited by 7
Targeting oncogenic protein kinase Cι for treatment of mutantKRASLADC
Fields, A. P., Ali, S. A., Justilien, V., & Murray, N. R. (2016) · Small GTPases · doi:10.1080/21541248.2016.1194953 · Cited by 7 · cited 1×
“Therefore, the inhibition of PKCι may be a rational approach to suppressing NSCLC, particularly in specific contexts such as mutant KRAS-expressing lung adenocarcinoma [68].”
BackgroundGao, Z., Tang, L., Su, B., Sha, H., & Han, B. (2007) · PubMed · doi:10.3779/j.issn.1009-3419.2007.06.02 · Cited by 2 · cited 1×
“The PKC inhibitor, chelerythrine chloride, decreased PKCαmRNA expression and protein levels and sensitized cisplatin-resistant A549 to cisplatin [43].”
Background
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“The activation of PKC can upregulate several molecular pathways, including Akt, signal transducer and activator of transcription 3 (STAT3), nuclear factor-κB (NF-κB) and apoptotic pathways, to regulate tumorigenesis andmetastasis [112].”
BackgroundOvercoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“Interestingly, different PKC isoforms play varying roles in tumorigenesis and metastasis (94).”
BackgroundZamanian, M. Y., Alsaab, H. O., Golmohammadi, M., Yumashev, A., Jabba, A. M., Abid, M. K., Joshi, A., Alawadi, A. H., Jafer, N. S., Kianifar, F., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4030 · Cited by 105
“82”
Silnitsky, S., Rubin, S. J. S., Zerihun, M., & Qvit, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417600 · Cited by 48
“PKC signaling pathways contribute to the key cellular responses central to asthma [283–285], chronic obstructive pulmonary disease (COPD) [286], idiopathic pulmonary fibrosis (IPF) [287], acute respiratory distress syndrome (ARDS) [288,289], and lung cancer [167,290], to mention a few.”
BackgroundHe, Q., Qu, M., Bao, H., Xu, Y., Shen, T., Tan, D., Barkat, M. Q., Xu, C., Zeng, L., & Wu, X. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.003 · Cited by 43
Metadata
- Authors
- Sadeghi, M. M., Salama, M. F., & Hannun, Y. A.
- Affiliations
- Department of Biochemistry, Molecular and Cellular Biology, Stony Brook University, Stony Brook, NY 11794, USA
- Mansoura University (EG)
- Stony Brook University Hospital (US)
- Corresponding author
- Hannun, Yusuf A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-05-24
- Volume
- 22
- Issue
- 11
- Pages
- 5527
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8197251
- OpenAlex
- W3164693058
- Cited by
- 31
- References
- 119
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 4 · 2021: 1
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Veterans Affairs (I01 BX004621)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- protein kinase C, non-small cell lung cancer, drug resistance, tyrosine kinase inhibitors, PKC isoforms, predictive biomarkers, combination therapy, targeted therapy
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Lung Neoplasms, Prognosis, Protein Kinase C, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Protein Isoforms, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.